Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. Its patented Trans-Arterial Micro-Perfusion therapy platform allows for targeted delivery of treatments to the tumor site while minimizing toxicities, potentially leading to improved efficacy. The company has made positive progress in its clinical drug development and commercialization efforts with increasing centers utilizing its FDA-cleared RenovoCath. With the potential for strong revenue growth and a new CFO with a successful track record, RenovoRx has a strong outlook.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company that has an attractive current valuation and has shown promising results in its TIGeR-PaC study. However, there are potential risks that could impact the company's ability to reach its share price target, including balance sheet and liquidity risks, potential failures in clinical trials, and competition in the market. Despite these risks, the company has a potential market worth billions of dollars, which could lead to high rewards for investors, making it an undervalued stock with a positive outlook for future growth.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.